蛋白酶体抑制剂与共刺激阻断脱敏降低DSA并延缓高致敏灵长类肾移植抗体介导排斥
研究在高致敏非人灵长类肾移植模型中,采用蛋白酶体抑制剂卡非佐米联合共刺激阻断剂贝拉西普进行术前脱敏。结果显示联合治疗显著降低供者特异性抗体和骨髓浆细胞,延长移植物存活并降低抗体介导排斥评分,但多数长期存活动物出现抗体反弹和排斥,提示术后需持续抑制B细胞反应。
要点
- 卡非佐米联合贝拉西普脱敏可降低DSA和骨髓浆细胞并延长移植物存活。
- 多数长期存活动物出现DSA反弹和抗体介导排斥,需术后持续免疫抑制。
- 该策略靶向生发中心反应和浆细胞,为高致敏肾移植提供潜在脱敏方案。
核心结论
- 蛋白酶体抑制联合共刺激阻断脱敏可减少骨髓浆细胞、扰乱生发中心反应、降低DSA水平并延长高致敏非人灵长类同种异体移植物存活。
- 多数动物出现体液反应反弹和抗体介导排斥,提示移植后需持续抑制B细胞反应以维持脱敏效果。
研究设计与样本
- 研究采用最大MHC错配的恒河猴配对,经两次序贯皮肤移植致敏。
- 六只动物每周接受卡非佐米和贝拉西普治疗1个月,四只对照不接受治疗。
- 在脱敏前、脱敏后及肾移植后分析血液、淋巴结、骨髓细胞和血清。
主要发现
- 与对照相比,治疗组供者特异性抗体水平显著降低(P=0.05),骨髓浆细胞显著减少(P=0.02)。
- 治疗组淋巴结T滤泡辅助细胞呈减少趋势(P=0.06)。
- 治疗组移植物存活显著延长(P=0.02),移植后1个月肾活检抗体介导排斥评分显著降低(P=0.02)。
- 五只长期存活动物中有四只出现DSA逐渐反弹和抗体介导排斥。
临床怎么用
- 在高致敏肾移植受者中,可考虑蛋白酶体抑制联合共刺激阻断作为术前脱敏策略。
- 脱敏后需在移植后持续监测DSA并维持B细胞反应抑制,以防范抗体介导排斥反弹。
局限性
- 研究为非人灵长类临床前模型,样本量小(治疗组6只、对照组4只),结论需在人体试验中验证。
- 长期存活动物多数出现DSA反弹和抗体介导排斥,提示单次脱敏方案持久性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with broad HLA sensitization have poor access to donor organs, high mortality while waiting for kidney transplant, and inferior graft survival. Although desensitization strategies permit transplantation via lowering of donor-specific antibodies, the B cell-response axis from germinal center activation to plasma cell differentiation remains intact. METHODS: To investigate targeting the germinal center response and plasma cells as a desensitization strategy, we sensitized maximally MHC-mismatched rhesus pairs with two sequential skin transplants. We administered a proteasome inhibitor (carfilzomib) and costimulation blockade agent (belatacept) to six animals weekly for 1 month; four controls received no treatment. We analyzed blood, lymph node, bone marrow cells, and serum before desensitization, after desensitization, and after kidney transplantation. RESULTS: The group receiving carfilzomib and belatacept exhibited significantly reduced levels of donor-specific antibodies (P=0.05) and bone marrow plasma cells (P=0.02) compared with controls, with a trend toward reduced lymph node T follicular helper cells (P=0.06). Compared with controls, carfilzomib- and belatacept-treated animals had significantly prolonged graft survival (P=0.02), and renal biopsy at 1 month showed significantly reduced antibody-mediated rejection scores (P=0.02). However, four of five animals with long-term graft survival showed gradual rebound of donor-specific antibodies and antibody-mediated rejection. CONCLUSIONS: Desensitization using proteasome inhibition and costimulation blockade reduces bone marrow plasma cells, disorganizes germinal center responses, reduces donor-specific antibody levels, and prolongs allograft survival in highly sensitized nonhuman primates. Most animals experienced antibody-mediated rejection with humoral-response rebound, suggesting desensitization must be maintained after transplantation using ongoing suppression of the B cell response.
引用
- Ezekian B, Schroder PM, Mulvihill MS, et al. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. J Am Soc Nephrol. 2019. PMID: 31658991. doi:10.1681/ASN.2019030304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。